Neurocrine Biosciences Inc

NASDAQ: NBIX
$137.54
-$1.35 (-1.0%)
Closing price April 30, 2024
Neurocrine Biosciences Inc is a biopharmaceutical company based in San Diego, California, focusing on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio includes INGREZZA for tardive dyskinesia, ALKINDI for adrenal insufficiency, and several products for conditions like Huntington’s disease, endometriosis, and uterine fibroids. The company is also advancing a range of candidates for conditions such as developmental and epileptic encephalopathy, major depressive disorder, and schizophrenia, among others. Neurocrine Biosciences maintains collaborations with various pharmaceutical companies to enhance its research and development efforts.
New research from Jefferies highlights this week's top growth stock picks, and there is a clear bias for some top biotech and pharmaceutical stocks — and with good reason. They are cheap and have...
This week's top U.S. growth calls from the analysts at Jefferies focus on companies that have some outstanding upside potential, including the following three leading biotech stocks.
Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as a year with some uncertainty.
Neurocrine Biosciences made waves in the market on Thursday morning after it announced positive results in a Phase 3 trial.
In a new report from Jefferies, three top growth stocks hit their screens and they all have substantial upside potential for aggressive growth investors.
Cowen sees the potential for super-mergers in biotech, as well as a large group of smaller targets that may be in the sights of bigger companies now.
Thursday's top analyst upgrades and downgrades include Chesapeake Energy, eBay, Enterprise Products Partners, Gilead Sciences, Newmont Mining and Wynn Resorts.
Wednesday's top analyst upgrades, downgrades and initiations includes Alcoa, Apache, Bob Evans, F5, Hain and McDonald's.
Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.
Thursday's top analyst upgrades, downgrades and initiations include Ally FInancial, Apple, Automatic Data Processing, Brocade Communications, Level 3 Communications and Tyco International.
In Thursday morning’s trading session, it seemed almost across the board that biotech stocks were the largest gainers.
Source: ThinkstockAfter being absolutely rocked back in the spring, the biotech sector has bounced back smartly. Even a bubble comment from the head of the Federal Reserve Janet Yellen didn’t stop...
With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good chance for investors to get timely updates on the top stocks and their...
Once again, the analysts at Piper Jaffray are conducting extensive management meetings with the companies they cover. Here are the seven top biopharma stocks to buy now, according to Piper Jaffray.
Investors and traders are often on the hunt for fresh research ideas that will lead to higher income or more profits in this choppy stock and volatile market. 24/7 Wall St. reviews many fresh...